The Family Heart Foundation, the leading research, education and advocacy organization focused on genetic dyslipidemias, has launched the Lp(a) AW(a)RE(TM) initiative to engage key U.S. healthcare ...
Lp(a)] has emerged as a major, genetically determined risk factor in atherosclerotic cardiovascular disease (ASCVD) and ...
A panel discussion titled “Elevated Lipoprotein(a): Raise Your Game and Lower Your (Risk) Score?” presented at the American Heart Association (AHA) Scientific Sessions 2023, which convened in ...
In a recent study published in the journal Current Medical Research and Opinion, researchers report that high lipoprotein(a) levels were linked to repeated coronary heart disease events in older ...
The study data support efforts to extend strategies for the primary prevention of atherosclerotic events beyond traditional 10-year estimates of risk. HealthDay News — A single combined measure of ...
A recent study published in the Virology Journal has highlighted the significance of high-density lipoprotein (HDL) in coronavirus disease 2019 (COVID-19) pathogenesis and outcome. A severely low ...
Following these positive 36-week results, Silence Therapeutics plans to announce 48-week results of the ongoing ALPACAR-360 study in Q2 of 2024. Silence Therapeutics has released promising findings ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback